FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2565496410> ?p ?o ?g. }

• W2565496410 endingPage "11" @default.
• W2565496410 startingPage "10" @default.
• W2565496410 abstract "A new device developed and investigated by scientists at the Massachusetts Institute of Technology (MIT) in Cambridge and the Dana-Farber Cancer Institute in Boston shows promise in testing cancer and other diseases for drug susceptibility. The technique, described in Nature Biotechnology, measures the masses of single cells to predict whether a particular drug will kill tumor cells on the basis of how the drug affects growth rates.1 The researchers successfully tested this approach with glioblastoma and lymphoblastic leukemia. According to the investigators, one advantage of this tool is that the analysis can be performed with very small numbers of cells. In leukemia cell experiments, for example, the researchers could obtain accurate results with a tiny droplet of blood containing approximately 1000 cancer cells. Another advantage of the method is the speed at which small changes in cell mass can be measured. This functional assay can measure the drug response of individual cells while maintaining viability for downstream analysis such as sequencing, according to senior author Scott Manalis, PhD, of MIT's Koch Institute for Integrative Cancer Research. The researchers were inspired by a test that has been used for many years to choose antibiotics to treat bacterial infections. With this method, bacteria are obtained from a patient and exposed to a range of antibiotics, and then one observes whether the bacteria grow or die. Dr. Manalis's laboratory uses a suspended microchannel resonator that can measure cell masses 10 to 100 times more accurately than any other technique, and this allows scientists to precisely calculate growth rates of single cells over short periods of time. In the study, the investigators analyzed different subtypes of glioblastoma and leukemia cells that had previously been shown to be either sensitive or resistant to specific therapies (MDM2 inhibitors for glioblastoma and BCR-ABL inhibitors for lymphocytic leukemia). After exposing the cancer cells to the drugs, the researchers found that cells known to be susceptible to a given therapy changed the way in which they accumulated mass, whereas resistant cells continued to grow as if unaffected. Now that Dr. Manalis and his team have a method for identifying cells that are not responding to a given therapy, he says that they can isolate and analyze the cells to understand the mechanisms of resistance." @default.
• W2565496410 created "2017-01-06" @default.
• W2565496410 creator A5062959891 @default.
• W2565496410 date "2016-12-16" @default.
• W2565496410 modified "2023-10-18" @default.
• W2565496410 title "Device rapidly measures cell growth and can help determine drug resistance in cancer" @default.
• W2565496410 cites W2530955838 @default.
• W2565496410 doi "https://doi.org/10.1002/cncr.30485" @default.
• W2565496410 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27983758" @default.
• W2565496410 hasPublicationYear "2016" @default.
• W2565496410 type Work @default.
• W2565496410 sameAs 2565496410 @default.
• W2565496410 citedByCount "0" @default.
• W2565496410 crossrefType "journal-article" @default.
• W2565496410 hasAuthorship W2565496410A5062959891 @default.
• W2565496410 hasBestOaLocation W25654964101 @default.
• W2565496410 hasConcept C114851261 @default.
• W2565496410 hasConcept C121608353 @default.
• W2565496410 hasConcept C126322002 @default.
• W2565496410 hasConcept C203014093 @default.
• W2565496410 hasConcept C2778461978 @default.
• W2565496410 hasConcept C2780035454 @default.
• W2565496410 hasConcept C3020340455 @default.
• W2565496410 hasConcept C502942594 @default.
• W2565496410 hasConcept C70721500 @default.
• W2565496410 hasConcept C71924100 @default.
• W2565496410 hasConcept C86803240 @default.
• W2565496410 hasConcept C89423630 @default.
• W2565496410 hasConcept C96232424 @default.
• W2565496410 hasConcept C98274493 @default.
• W2565496410 hasConceptScore W2565496410C114851261 @default.
• W2565496410 hasConceptScore W2565496410C121608353 @default.
• W2565496410 hasConceptScore W2565496410C126322002 @default.
• W2565496410 hasConceptScore W2565496410C203014093 @default.
• W2565496410 hasConceptScore W2565496410C2778461978 @default.
• W2565496410 hasConceptScore W2565496410C2780035454 @default.
• W2565496410 hasConceptScore W2565496410C3020340455 @default.
• W2565496410 hasConceptScore W2565496410C502942594 @default.
• W2565496410 hasConceptScore W2565496410C70721500 @default.
• W2565496410 hasConceptScore W2565496410C71924100 @default.
• W2565496410 hasConceptScore W2565496410C86803240 @default.
• W2565496410 hasConceptScore W2565496410C89423630 @default.
• W2565496410 hasConceptScore W2565496410C96232424 @default.
• W2565496410 hasConceptScore W2565496410C98274493 @default.
• W2565496410 hasIssue "1" @default.
• W2565496410 hasLocation W25654964101 @default.
• W2565496410 hasLocation W25654964102 @default.
• W2565496410 hasOpenAccess W2565496410 @default.
• W2565496410 hasPrimaryLocation W25654964101 @default.
• W2565496410 hasRelatedWork W2097641937 @default.
• W2565496410 hasRelatedWork W2913256810 @default.
• W2565496410 hasRelatedWork W2938150871 @default.
• W2565496410 hasRelatedWork W2946241187 @default.
• W2565496410 hasRelatedWork W3011352832 @default.
• W2565496410 hasRelatedWork W3112234767 @default.
• W2565496410 hasRelatedWork W3112602333 @default.
• W2565496410 hasRelatedWork W3134731358 @default.
• W2565496410 hasRelatedWork W3204245326 @default.
• W2565496410 hasRelatedWork W4300943664 @default.
• W2565496410 hasVolume "123" @default.
• W2565496410 isParatext "false" @default.
• W2565496410 isRetracted "false" @default.
• W2565496410 magId "2565496410" @default.
• W2565496410 workType "article" @default.